TX-EAGLE-EYE-NETWORKS
27.10.2020 11:02:09 CET | Business Wire | Press release
Eagle Eye Networks, the global leader in cloud video surveillance, has raised $40 million of Series E funding from venture capital firm Accel (Facebook, Spotify, DocuSign) to continue its growth and expand its technology leadership. Eagle Eye is leveraging artificial intelligence (AI) on its true cloud platform to dramatically reshape video surveillance and improve safety, security, operations, and customer service for businesses around the world.
Today’s video surveillance systems have multiple security features, such as motion detection and standard analytics. However, these systems require either monotonous monitoring or a meticulous manual review after each triggered event to extract useful information. Similarly, business operations analytics are still in early development.
“There is a tremendous opportunity to leverage AI and alter the very nature of video surveillance,” said Dean Drako, Founder and CEO of Eagle Eye Networks. “Eagle Eye Networks now has the means and the technology to enable cloud video surveillance to transform how companies manage security and business operations, in the same way self-driving and electric cars are transforming transportation.
“Ultimately, smart cloud video surveillance with appropriate privacy and cybersecurity protections will make business and communities much safer, for example: detecting dangers such as weapons, erratic driving, active robberies, and traffic accidents. Furthermore,” continued Drako, “businesses will analyze their customer service and retail operations to provide a significantly better customer experience, and manufacturers will provide higher quality products, in a safer and more timely manner with video AI.”
Sameer Gandhi, Partner at Accel, added, “Eagle Eye Networks pioneered the video surveillance industry’s move to the cloud, and AI applications will drive the industry’s next transformation. Eagle Eye is in the pole position to make this happen. Its true cloud technology puts Eagle Eye in a unique position to instantly deploy new analytics breakthroughs. Dean Drako’s track record, proven with Eagle Eye and previously as founder of Barracuda Networks, speaks for itself.”
Eagle Eye Networks Cloud VMS
The Eagle Eye Cloud Video Management System (VMS) is a smart cloud video surveillance solution, purpose-built to help businesses improve safety, security, operations, and customer service while saving money. Tens of thousands of companies in more than 90 countries around the globe have moved their video surveillance to the cloud with Eagle Eye VMS. Customers, including multi-family residences, smart cities, schools, hospitals, hotels, logistics, restaurants, and retail shops trust Eagle Eye for actionable business intelligence and proactive security.
Eagle Eye Cloud VMS offers comprehensive central management, cloud reliability and redundancy, cost savings, and an open API video platform that provides a vast number of third-party integrations. Customers appreciate Eagle Eye’s inherent cyber secure design and extensive video encryption to protect their data and privacy. The Eagle Eye Cloud VMS works with thousands of industry cameras and does not require customers to “rip and replace” their existing infrastructure.
Eagle Eye Networks, together with its partner Brivo, provide a seamless solution for cloud video surveillance and facility access control. Brivo is the worldwide leader in cloud facility access control. The Eagle Eye API allows for seamless integration with partners like Brivo and others making Eagle Eye Cloud VMS the only platform robust enough to power the future of video surveillance.
“In more than two decades in the video surveillance industry, I have heard people talk about revolutionizing the market and taking it to the next level, but only Eagle Eye Networks has truly delivered on that promise,” added John E. Mack III, Executive Vice President, Co-Head of Investment Banking at Imperial Capital. “While Eagle Eye Networks vision as the first cloud native solution was compelling previously, the changes 2020 brought about through business disruption related to COVID-19 make Eagle Eye’s products and services even more desirable. Eagle Eye’s focus on the customer and commitment to innovation create a foundation that makes its cloud and AI enhanced offerings for video surveillance a focus for security specific executives and the C-suite alike.”
ABOUT EAGLE EYE NETWORKS
Founded in 2012, Eagle Eye Networks, Inc., is #1 in cloud video surveillance worldwide, addressing the needs of businesses, alarm companies, security integrators, cities, and individuals. Eagle Eye’s 100% cloud managed solutions provide cloud and on-premise recording, bank-level security and encryption, and broad analog and digital camera support – all accessed via the web or mobile applications. Businesses of all sizes and types utilize Eagle Eye solutions for operational optimization and security. All Eagle Eye products benefit from Eagle Eye’s developer friendly RESTful API platform and Big Data Video Framework ™, which allow for indexing, search, retrieval, and analysis of live and archived video. Eagle Eye’s open Video API has been widely adopted for integration in alarm monitoring, third party analytics, security dashboards, and point of sale system integrations.
Eagle Eye sells its products through authorized global resellers and installation partners. Headquartered in Austin, Texas, USA, Eagle Eye has offices in Europe and Asia-Pacific. For more information, please visit www.een.com or call +1-512-473-0500 (US), +31 (0) 20 26 10 460 (EMEA) or +81-3-6868-5527 (JP).
ABOUT ACCEL
Accel is a global venture capital firm that is the first partner to exceptional teams everywhere, from inception through all phases of private company growth. Atlassian, Braintree, Cloudera, Crowdstrike, DJI, DocuSign, Dropbox, Etsy, Facebook, Flipkart, Freshworks, Jet, Pillpack, Qualtrics, Slack, Spotify, Supercell, Tenable, UiPath, and Venmo are among the companies Accel has backed over the past 35+ years. We help ambitious entrepreneurs build iconic global businesses. For more, visit www.accel.com or www.twitter.com/accel .
View source version on businesswire.com: https://www.businesswire.com/news/home/20201027005276/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom